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The technique of endoscopic submucosal dissection (ESD) has been developed for en bloc resection of early gastric cancer (EGC);
however, little is known about the risk of metachronous cancer in the remnant stomach after initial ESD. In this study, we investigated
the correlation between microsatellite instability (MSI) status and the incidence of metachronous recurrence of gastric cancer.
According to the genetic/molecular background determined with MSI status and expression levels of hMLH1 and p53 tumour
suppressor, 110 EGCs removed with ESD were subclassified into three groups: the mutator/MSI-type (8%), suppressor/p53-type
(45%) and unclassified type (47%). Interestingly, patients with the mutator/MSI-type tumour had a high incidence (67%) of
metachronous recurrence of gastric cancer within a 3-year observation after initial ESD, which was significantly higher than those with
the suppressor/p53-type and unclassified type tumours (Po0.01). Although we investigated mucin phenotypes, there was no
correlation between mucin phenotype and the recurrence of EGC. These findings suggest that subclassification of molecular
pathological pathways in EGCs is required for the assessment of patients with a high risk of recurrent gastric cancer. The information
delivered from our investigation is expected to be of value for decisions about therapy and surveillance after ESD.
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Gastric cancer is the second-most-frequent malignant tumour
worldwide, but the consequences of early gastric cancer (EGC) are
comparatively good (Correa, 1992). In particular, endoscopic
treatment is being widely used to treat patients with EGC and
carries with it some improvement for their prognosis; therefore,
many patients suffering from EGC have avoided laparotomy and
maintained a better quality of life (Nagano et al, 2005). Endoscopic
resection of EGC is now the standard therapy in Japan and is
increasingly becoming accepted and regularly used in other
countries. Recently, an innovational technique for endoscopic
submucosal dissection (ESD) has been developed for en bloc
resection of ECG (Ono et al, 2001). In addition, the ESD method
has made it possible to give an accurate diagnosis by pathological
examination (Toyonaga et al, 2006). However, metachronous
recurrence at other sites in the stomach, after initial endoscopic
treatment, has been identified as a major problem (Hamanaka and
Gotoda, 2005).
Based on the tendency of gland formation, gastric carcinomas
have been divided into two main histological types: diffuse-type
carcinomas, which may arise from native gastric epithelial cells,
and intestinal-type carcinomas, which were thought to arise from
gastric epithelial cells that have undergone intestinal metaplasia
(Lauren, 1965; Nakamura et al, 1968; Tahara, 1995). Current
accepted indications for ESD of EGC include the resection of
small intramucosal EGC of the intestinal type; the development of
ESD techniques enables resection of larger lesions than has been
technically feasible by simple endoscopic mucosal resection
(EMR). However, the rationale behind this recommendation was
that larger size lesions, or lesions with diffuse histology type,
may extend into the submucosal layer and thus have a higher risk
of lymph node metastasis. Therefore, at present, the accepted
indications for ESD are: (i) well-differentiated elevated cancers
less than 2cm in size and (ii) small (p1cm) depressed lesions
without ulceration (Japanese Gastric Cancer Association, 2001).
These lesions must also be moderately or well differentiated and
confined to the mucosa, and must not have lymphatic or vascular
involvement; well-differentiated type adenocarcinomas correspond
to the intestinal-type (Lauren, 1965), the expanding-type (Ming,
1977) and the differentiated carcinoma (Nakamura et al, 1968).
Recent molecular biological studies have revealed that there
are at least two distinct genetic pathways for gastrointestinal
carcinogenesis, the suppressor and mutator pathways (Parsons
et al, 1993; Eshleman and Markowitz, 1996). The suppressor/p53
pathway is mainly caused by inactivation of tumour suppressor
genes and the activation of oncogenes. p53 is a tumour suppressor
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sthat is frequently mutated in human cancer and is believed to play
an important role in defending against cancer (Tamura et al, 1995).
Microsatellite instability (MSI) is closely correlated with genetic
instability, particularly in hereditary nonpolyposis colorectal
cancer (HNPCC) (Fishel et al, 1993; Peltomalo et al, 1993).
Dysfunction of the DNA mismatch repair system leads to the
mutator pathway showing MSI; thus, MSI can be identified in
tumours when alleles of novel sizes are detected in microsatellite
sequences derived from cancer DNA that are not present in the
normal tissue of the same individual. It has been documented that
15–33% of human gastric cancers exhibit MSI and that MSI is
frequently observed in well-differentiated adenocarcinoma
(Mironov et al, 1994; Semba et al, 1996). Furthermore, MSI was
observed more frequently in patients with synchronous multiple
gastric tumours than in those with a single tumour (Nakashima
et al, 1995).
In this study, we focused on the metachronous recurrence of
gastric cancer after removal of EGC (well-differentiated type) with
ESD. After initial dissection, we subclassified these patients into
three groups according to molecular findings and followed them
endoscopically for several years to monitor the recurrence of
gastric cancer.
MATERIALS AND METHODS
Patients and DNA extraction
The series consisted of 110 patients who had undergone curative
resections for EGC with ESD at the Kobe University Hospital from
2000 to 2004. Their clinical and histological characteristics are
summarised in Table 1. Informed consent for the scientific analysis
of resected specimens was obtained from all patients, including
those who had no hereditary cancer syndrome history, such as
HNPCC, Li-Fraumeni syndrome and familial adenomatous poly-
posis (FAP), and those who had hereditary diffuse gastric cancer
(HDGC). All resected specimens were fixed in 10% formalin and
embedded in paraffin. Histopathological examination was per-
formed according to the Japanese Classification of Gastric
Carcinoma 2nd edition (Japanese Gastric Cancer Association,
2001). Early gastric cancers were defined as cancers in which
invasion was limited to the submucosal layer, irrespective of the
presence or absence of metastasis to lymph nodes. To exclude
the incidence of local recurrence after initial ESD treatment, the
histological curative resection was determined as follows; depth M
(mucosa), histologically well differentiated adenocarcinoma (tub1
or tub2), neither lymphatic nor venous invasion, no tumour cells
within 1mm of lateral margin (1mm lateral margin approximately
corresponds to the length of ten tubules). The cases positive for
lateral or vertical margins were therefore avoided in this study.
Selected blocks were sectioned into 4mm-thick slices for DNA
extraction and immunohistochemical analysis. For DNA extrac-
tion, the deparaffinised specimens were stained with haematoxylin
and eosin (H&E). The tumour areas and corresponding non-
neoplastic gastric mucosa were scraped using a sterile needle and
placed in a microtube containing extraction buffer before being
incubated at 551C for 12h as described elsewhere (Wu et al, 2004).
Proteinase K was inactivated by boiling for 5min after inactivation
and then the DNAs were used for polymerase chain reaction
(PCR).
Immunohistochemistry
Immunohistochemical analyses were carried out with monoclonal
antibodies to p53 (DakoCytomation, Copenhagen, Denmark),
hMLH1 (BD Biosciences, San Diego, CA, USA), CD10 (Novocastra
Laboratories, Newcastle-upon-Tyne, UK), MUC2 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), MUC5AC (Novocastra
Laboratories) and MUC6 (Novocastra Laboratories). Dewaxed
and rehydrated specimens were autoclaved in citrate buffer for the
antigen retrieval. Endogenous peroxidase activity and nonspecific
binding were blocked by 0.03% hydrogen peroxidase in methanol
and blocking reagent in LSAB2 kit (DakoCytomation), respec-
tively. The slides were then incubated with the primary mono-
clonal antibody and incubated sequentially with a biotinylated
secondary antibody, streptavidin, labelled with peroxidase and 3,
30-diaminobenzidine. Slides were counterstained with Mayer’s
haematoxylin. Immunoreactivity of p53 and hMLH1 was graded as
follows: almost no positive cells; þ, o25% of the tumour cells
showed positive immunoreactivity; þþ, 25–50% of the tumour
cells showed positive immunoreactivity; þþþ, 450% of the
tumour cells showed positive immunoreactivity (Li et al, 2005).
Microsatellite analysis
Nine microsatellite markers (BAT-25, BAT-26, BAT-40, BAT-RII,
D1S191, D2S123, D5S346, D17S250 and D17S855) were analysed
(Li et al, 2005). The forward primers were fluorescein labelled with
6-FAM (D1S191, D17S250, BAT-26 and BAT-40), HEX (D17S855
and BAT-RII), VIC (D5S346) and TAMRA (D2S123 and BAT-25).
PCR was performed in 15ml reaction volumes containing 1ml
template DNA, 0.56mmoll
 1 of each primer, 74.7mmoll
 1 of
dNTP, 4.5mmoll
 1 of MgCl2 and 0.075U of AmpliTaq Gold
(Applied Biosystems, Foster City, CA, USA). After the initial Taq
DNA polymerase activation step, the PCR amplification consisted
of 45 cycles (941C for 45s, 551C for 45s and 721C for 45s) followed
by a final extension for 10min at 721C. Polymerase chain reaction
products were electrophoresed in ABI PRISM 310 Genetic Analyzer
along with GeneScan-500 (ROX) molecular weight standard
(Applied Biosystems). The size of the PCR product was analysed
using GeneScan software (Applied Biosystems). The status of MSI
in each tumour was evaluated according to the criterion of Boland
et al (1998); MSI-H, if three or more out of nine microsatellite
loci showed MSI; MSI-L, if one or two loci had MSI; MSS, if all
the microsatellite loci examined were stable. Alleles were defined
as the two highest peaks (tumour DNA alleles, T1, T2; normal
DNA alleles, N1, N2) and a ratio of (T1/T2)/(N1/N2) of o0.67 or
41.50 was scored as a loss of heterozygosity (LOH) (Wu et al,
2004).
Subclassification of mucin phenotypes
The extent of positivity for MUC2, MUC5AC, MUC6 and CD10 was
scored according to the percentage of neoplastic cells stained:  ,
no positive cells or essentially none (o5%); þ, some positive cells
(5–30%); þþ, well-defined areas of positive cells (30–60%);
Table 1 Clinical and histological characteristics of early gastric cancers
Characteristic Group No. (%)
Gender Male 74 (67)
Female 36 (33)
Age
a(year) o65 53 (48)
X65 57 (52)
Tumour size (cm) o2 67 (61)
X2 43 (39)
Location
b Upper 30 (27)
Middle 31 (28)
Lower 49 (45)
Differentiation
b tub1 84 (76)
tub2 26 (24)
aAverage age (years); 65.377.3.
bLocation of tumours and histological differentiation
were determined according to the Japanese Classification of Gastric Cancer 2nd
edition. tub1¼well-differentiated tubular adenocarcinoma, tub2¼moderately
differentiated tubular adenocarcinoma.
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sþþþ, extensive areas of positive cells (460%). According to the
sums of scores of gastric markers (MUC5AC, MUC6) and intestinal
markers (MUC2, CD10), each case was phenotypically classified
into three phenotypes: the gastric phenotype, mixed phenotype
and intestinal phenotype (Tsukashita et al, 2001).
Statistical analysis
Statistical comparisons were performed using the Fisher’s
protected least significant difference test, the w
2 test, the log-rank
test and the Kaplan–Meier test for three independent groups.
P-values of 0.05 or less were considered to indicate statistical
significance. All statistical analyses were performed using Statview
5.0 software (SAS Institute Inc., Cary, NC, USA).
RESULTS
Subclassification of EGC with genetic background: the
mutator/MSI-type and suppressor/p53-type
To determine the genetic background of each tumour, we first
performed a microsatellite assay in tumours with microsatellite
markers (Figure 1A). Overall, MSI was detected in 25 (23%) of 110
cases (MSI-H, nine (8%) cases; MSI-L, 16 (15%) cases) and LOH at
the p53 locus (D17S250) was detected in eight (7%) of 110 cases
(Figure 1B and 2). Next, we investigated the levels of p53 and
hMLH1 expression immunohistochemically to distinguish the
mutator/MSI-type tumours and suppressor/p53-type tumours.
Strong nuclear accumulation of p53 (þþ, þþþ) was detected
in 47 (43%) cases and loss of hMLH1 expression ( ) was detected
in 28 (25%) cases, respectively (Figures 1C and 2).
Two distinct pathways, the mutator and suppressor pathways,
have been proposed for colorectal carcinogenesis (Parsons et al,
1993). Similarly, this concept is believed to be available for
subclassification of human gastric cancers (Yamamoto et al, 1995;
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Figure 1 Representative results of microsatellite assay and immunohis-
tochemistry. (A) Results of microsatellite analysis on BAT-25, BAT-40 and
D17S250. Arrowheads indicate MSI. N, normal mucosa; T, tumour. (B)
Loss of heterozygosity at the p53 locus (D17S250). Decreased peak levels
in tumour are regarded as LOH (arrow). N, normal mucosa; T, tumour. (C)
Histological examination of EGCs. Representative mutator/MSI-type (a, c, e;
 100) and suppressor/p53-type (b, d, f;  100) tumours are illustrated.
a–b, H&E.; c–d, p53; d–f, hMLH1 (inset original magnification  400).
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Figure 2 Results of microsatellite assay and immunohistochemical
analyses (IHC) in the mutator/MSI-type and suppressor/p53-type human
EGCs. The status of microsatellite sequences was determined as described
in the text. Immunoreactivity of p53 and hMLH1 was graded from   to
þþþ. According to these results, tumours were subclassified into the
mutator/MSI-type, suppressor/p53-type, and unclassified type tumours.
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sSemba et al, 1996; Endoh et al, 2000; Furlan et al, 2002; Wu et al,
2004). Therefore, we attempted to subclassify these EGCs with
the definition of the mutator (mutator/MSI-type) and suppressor
(suppressor/p53-type) pathways (Eshleman and Markowitz, 1996).
According to the results of genetic and immunohistochemical
analyses, we therefore subclassified these EGCs into three
subtypes: the mutator/MSI-type (tumours with MSI-H and loss
of hMLH1 expression), nine (8%) cases; suppressor/p53-type
(tumour with strong p53 expression, or with LOH at D17S250),
49 (45%) cases and unclassified type, 52 (47%) cases (Figure 2 and
Table 2). All of the cases of the mutator/MSI-type tumours showed
loss of hMLH1 expression, whereas 41 of 49 (84%) and 27 of 52
(52%) cases in the suppressor/p53 and unclassified types had
strong expression of hMLH1. No significant correlation was found
between genetic type and clinicopathological parameters.
Expression of epithelial mucin in EGCs
We investigated mucin expression in these EGCs because a
previous study reported that subclassification of gastric cancer
mucin is likely to be useful in predicting the pattern of gastric
carcinoma recurrence after curative surgery (Tajima et al, 2004).
According to the results of immunohistochemical analyses of
epithelial mucin expression, the EGCs were classified into three
mucin phenotypes: the gastric phenotype, 50 (46%) cases; mixed
phenotype, 17 (15%) cases and intestinal phenotype, 43 (39%)
cases. There was significant difference between mucin phenotypes
and location (P¼0.007), but no correlation was found in the other
clinicopathological parameters (Table 2).
MSI status is a good marker for the possible development
of metachronous cancer
The patients examined were regularly followed and observed
endoscopically to monitor for secondary metachronous tumours
in the remnant stomach after ESD. Interestingly, patients with
mutator/MSI-type EGCs had a tendency to develop secondary
metachronous cancer in the remnant stomach after initial ESD,
which was statistically higher than the suppressor/p53 and
unclassified type tumours (Po0.01, Figure 3A), whereas no
correlation was found in the increase of metachronous gastric
cancers by subclassification of tumours with mucin phenotypes
(P¼0.84, Figure 3B). We also investigated MSI and p53 and
hMLH1 expression in the metachronous secondary gastric cancers;
all secondary tumours arising from patients with the mutator/MSI-
type EGC also showed MSI and loss of hMLH1 expression (data
not shown).
DISCUSSION
Endoscopic treatment for patients with early-stage gastric
carcinoma has been widely used for curative therapy, and such
endoscopic tumour resection has enabled patients with gastric
cancer to have better prognoses (Haruma et al, 1990; Sano et al,
1992; Amano et al, 1998). Although ESD is a useful method newly
developed not only for endoscopic curative resection of EGCs
but also for accurate histological diagnosis, the indications for
such endoscopic treatment are limited to small, well-differentiated
adenocarcinomas with minimal submucosal invasion (Hirasaki
et al, 2005; Kato, 2005). Endoscopic treatment excised only gastric
carcinoma tissues, which implies that patients are still at risk of
developing metachronous recurrence of gastric cancer. Therefore,
molecular diagnosis is required for the screening of patients
expected to have metachronous gastric carcinoma (Miyoshi et al,
2001).
This is the first report indicating the clinical usefulness of
microsatellite analysis for predicting the potential risk of deve-
loping metachronous gastric cancer after curative resection with
ESD. Miyoshi et al (2001) examined MSI retrospectively in patients
with multiple EGCs and found that MSI increased the frequency
of synchronous and metachronous gastric cancer development.
However, gastric carcinoma tissues removed with EMR may
possibly be related to local recurrence of carcinoma, and
Table 2 Relationship between genetic type/mucin phenotype and clinicopathological parameters in early gastric cancers
Genetic type Mucin phenotype
Mutator/MSI Suppressor/p53 Unclassified P-value Gastric Mixed Intestinal P-value
Gender
Male 6 32 36 34 11 29
Female 3 17 16 0.931 16 6 14 0.989
Age (years)
o65 4 20 29 23 7 23
X65 5 29 23 0.424 27 10 20 0.804
Tumour size (cm)
o2 7 30 30 30 9 28
X2 2 19 21 0.774 20 8 15 0.840
Location
a
Upper 2 12 14 20 4 6
Middle 4 13 14 16 7 8
Lower 3 24 24 0.969 14 6 29 0.007*
Differentiation
a
tub1 7 38 39 34 13 37
tub2 2 11 13 0.956 16 4 6 0.192
Total (%) 9 (8) 49 (45) 52 (47) 50 (46) 17 (15) 43 (39)
aLocation and histological differentiation of the tumours were determined according to the Japanese Classification of Gastric Cancer 2nd edition (2001). tub1¼ well-
differentiated tubular adenocarcinoma, tub2¼ moderately differentiated tubular adenocarcinoma. *There was significant difference between mucin phenotypes and location of
EGC (P¼0.007, Fisher’s test).
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sresearchers collected multiple EGC tissues with the intention of
analysing the relationship between MSI and synchronous and
metachronous gastric cancer. In the current study, we could
eliminate the local recurrence of gastric cancer because ESD is a
more efficient method for curative resection of EGC and enables
more accurate histopathological diagnosis than EMR. In addition,
our cohort study indicated a high frequency of MSI linked with
recurrence of carcinoma in patients with EGC. Thus, subclassifica-
tion of EGCs into two distinct groups, the mutator/MSI-type and
the suppressor/p53-type, may help clinically in defining a
molecular marker for the prediction of multiple and metachronous
gastric cancer.
Correa (1992) hypothesised that carcinogenesis of the stomach
is a multistage process, and the progression from normal epithelial
cells to tumour cells involves at least six stages: superficial gastritis,
chronic atrophic gastritis, intestinal metaplasia of the complete
type followed by the incomplete type, gastric adenoma, dysplasia
and carcinoma. Although chronic infection of Helicobacter pylori
(H. pylori) (Blaser, 1987) and excess salt and nitrosamine
compound intake (Sugimura and Wakabayashi, 1990) are sus-
pected to be important causal factors in gastric carcinogens, little
is known about the mechanism through which the incidence of
gastric cancer might be increased. In this study, infection of
H. pylori was confirmed in all cases, and eradication treatment was
performed before or after ESD; the eradication therapeutic success
rate was 95%, and a second eradication treatment using another
antibiotic was performed in the failure group (data not shown).
The data suggest that chronic atrophic gastritis with or without
intestinal metaplasia, due to H. pylori infection, certainly increases
the incidence of gastric cancer, irrespective of the mutator/MSI-
type or the suppressor/p53-type. However, further genetic changes
may finally decide the carcinogenesis pathway for epithelial cells to
develop gastric cancer. As reported previously, an MSI-positive
genetic background is a risk for developing multiple cancers,
including synchronous and metachronous cancer (Miyoshi et al,
2001). As our study indicated that patients with the mutator/
MSI-type EGC are expected to have a higher risk of developing
metachronous mutator/MSI-type tumours in the stomach, the
assessment of MSI is necessary for following up these patients with
MSI-positive EGC.
Tajima et al (2004) showed that the incidence of gastric mucin-
producing tumours was significantly higher in tumours with
recurrence than in tumours without recurrence after curative
surgery, irrespective of their histological type. Their study was
performed using advanced cancer; presumably, the results may
have been influenced by the other characteristic factors of cancer
cells, including resistance to chemotherapy, growth rate and vessel
infiltration activity. No significant correlation was found between
MSI and mucin phenotype in this series of EGC, in which most
tumours demonstrated well-differentiated tubular formation (tub1
and tub2), suggesting that recurrence of gastric cancer may not
be controlled by mucin phenotype (Shibata et al, 2003). Although
it has also been documented that mucin phenotype may be
associated with MSI status (Endoh et al, 2000; Takahashi et al,
2002), our results indicate the opposite conclusion; mucin
phenotypes did not connect with genetic alterations in micro-
satellite loci. Further investigation is required to clarify this
discrepancy.
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